Philadelphia chromosome

The Philadelphia chromosome results from a balanced translocation between chromosome 9 (ABL1 gene) and chromosome 22 (BCR gene), t(9;22)(q34;q11). This fusion produces the BCR-ABL1 oncoprotein, which has constitutive tyrosine kinase activity, driving uncontrolled myeloid cell proliferation independent of normal growth signals. This is the defining cytogenetic abnormality in chronic myelogenous leukemia (CML), present in over 90-95% of patients, and can also be identified in about 20-30% of adult ALL cases (and a smaller percentage of pediatric ALL), where its presence indicates a worse prognosis. Clinically, CML presents with marked leukocytosis, splenomegaly, and a peripheral smear showing a full spectrum of granulocytic maturation (basophilia is characteristic). Diagnosis is confirmed via cytogenetic testing (karyotype, FISH) or molecular testing (RT-PCR) for BCR-ABL1 transcripts. The discovery of this fusion protein led to the development of tyrosine kinase inhibitors (TKIs) such as imatinib, dasatinib, and nilotinib, which target the ABL kinase domain and have revolutionized CML treatment, converting it from a fatal disease to a chronic, manageable condition in most patients. Resistance can develop due to point mutations in the ABL kinase domain (e.g., T315I mutation), which may require second- or third-generation TKIs like ponatinib. In ALL, Philadelphia chromosome positivity necessitates the addition of TKI therapy to standard chemotherapy regimens due to the aggressive nature of Ph+ ALL.